Novartis AG ADR (NVS)vsTeleflex Incorporated (TFX)
NVS
Novartis AG ADR
$148.38
-0.55%
HEALTHCARE · Cap: $273.77B
TFX
Teleflex Incorporated
$129.84
-1.72%
HEALTHCARE · Cap: $5.78B
Smart Verdict
WallStSmart Research — data-driven comparison
Novartis AG ADR generates 2560% more annual revenue ($56.58B vs $2.13B). NVS leads profitability with a 23.9% profit margin vs -47.4%. TFX appears more attractively valued with a PEG of 0.16. TFX earns a higher WallStSmart Score of 63/100 (C+).
NVS
Hold49
out of 100
Grade: D+
TFX
Buy63
out of 100
Grade: C+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-62.1%
Fair Value
$91.39
Current Price
$148.38
$56.99 premium
Margin of Safety
-0.7%
Fair Value
$106.26
Current Price
$129.84
$23.58 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 35 in profit
Strong operational efficiency at 30.5%
Keeps 24 of every $100 in revenue as profit
Generating 2.9B in free cash flow
Growing faster than its price suggests
Revenue surging 32.3% year-over-year
Earnings expanding 64.1% YoY
Conservative balance sheet, low leverage
Reasonable price relative to book value
Areas to Watch
Grey zone — moderate risk
Elevated debt levels
Expensive relative to growth rate
Revenue declined 0.7%
Distress zone — elevated risk
Premium valuation, high expectations priced in
ROE of -32.7% — below average capital efficiency
Currently unprofitable
Comparative Analysis Report
WallStSmart ResearchBull Case : NVS
The strongest argument for NVS centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 23.9% and operating margin at 30.5%.
Bull Case : TFX
The strongest argument for TFX centers on PEG Ratio, Revenue Growth, EPS Growth. Revenue growth of 32.3% demonstrates continued momentum. PEG of 0.16 suggests the stock is reasonably priced for its growth.
Bear Case : NVS
The primary concerns for NVS are Altman Z-Score, Debt/Equity, PEG Ratio.
Bear Case : TFX
The primary concerns for TFX are Altman Z-Score, P/E Ratio, Return on Equity. A P/E of 1864.0x leaves little room for execution misses.
Key Dynamics to Monitor
NVS profiles as a declining stock while TFX is a hypergrowth play — different risk/reward profiles.
TFX carries more volatility with a beta of 0.82 — expect wider price swings.
TFX is growing revenue faster at 32.3% — sustainability is the question.
NVS generates stronger free cash flow (2.9B), providing more financial flexibility.
Bottom Line
TFX scores higher overall (63/100 vs 49/100) and 32.3% revenue growth. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Novartis AG ADR
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Novartis AG researches, develops, manufactures and markets medical devices worldwide. The company is headquartered in Basel, Switzerland.
Visit Website →Teleflex Incorporated
HEALTHCARE · MEDICAL INSTRUMENTS & SUPPLIES · USA
Teleflex Incorporated, headquartered in Wayne, Pennsylvania, is an American provider of specialty medical devices for a range of procedures in critical care and surgery.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?